KR100910928B1 - 신경퇴행성 질환의 예방 또는 치료용의 카바메이트 화합물 함유 약제학적 조성물 - Google Patents

신경퇴행성 질환의 예방 또는 치료용의 카바메이트 화합물 함유 약제학적 조성물 Download PDF

Info

Publication number
KR100910928B1
KR100910928B1 KR1020037011302A KR20037011302A KR100910928B1 KR 100910928 B1 KR100910928 B1 KR 100910928B1 KR 1020037011302 A KR1020037011302 A KR 1020037011302A KR 20037011302 A KR20037011302 A KR 20037011302A KR 100910928 B1 KR100910928 B1 KR 100910928B1
Authority
KR
South Korea
Prior art keywords
disease
formula
compound
delete delete
dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037011302A
Other languages
English (en)
Korean (ko)
Other versions
KR20030076714A (ko
Inventor
플라타-살라만카를로스알
자오보유
트와이만로이이
Original Assignee
오르토-맥네일 파마슈티칼, 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오르토-맥네일 파마슈티칼, 인코퍼레이티드 filed Critical 오르토-맥네일 파마슈티칼, 인코퍼레이티드
Publication of KR20030076714A publication Critical patent/KR20030076714A/ko
Application granted granted Critical
Publication of KR100910928B1 publication Critical patent/KR100910928B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020037011302A 2001-02-27 2002-02-21 신경퇴행성 질환의 예방 또는 치료용의 카바메이트 화합물 함유 약제학적 조성물 Expired - Fee Related KR100910928B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27168201P 2001-02-27 2001-02-27
US60/271,682 2001-02-27
US10/081,764 2002-02-21
US10/081,764 US20020165273A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders
PCT/US2002/005541 WO2002067925A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Publications (2)

Publication Number Publication Date
KR20030076714A KR20030076714A (ko) 2003-09-26
KR100910928B1 true KR100910928B1 (ko) 2009-08-06

Family

ID=26765943

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037011302A Expired - Fee Related KR100910928B1 (ko) 2001-02-27 2002-02-21 신경퇴행성 질환의 예방 또는 치료용의 카바메이트 화합물 함유 약제학적 조성물

Country Status (26)

Country Link
US (3) US20020165273A1 (https=)
EP (1) EP1383489B1 (https=)
JP (1) JP4276840B2 (https=)
KR (1) KR100910928B1 (https=)
CN (1) CN1235579C (https=)
AR (1) AR035756A1 (https=)
AT (1) ATE361745T1 (https=)
BR (1) BR0207645A (https=)
CA (1) CA2439295C (https=)
CY (1) CY1106753T1 (https=)
CZ (1) CZ301203B6 (https=)
DE (1) DE60220043T2 (https=)
DK (1) DK1383489T3 (https=)
ES (1) ES2284845T3 (https=)
HU (1) HUP0303264A3 (https=)
IL (2) IL157591A0 (https=)
MX (1) MXPA03007718A (https=)
MY (1) MY138156A (https=)
NO (1) NO20033798L (https=)
NZ (1) NZ527990A (https=)
PL (1) PL364680A1 (https=)
PT (1) PT1383489E (https=)
RS (1) RS51055B (https=)
RU (1) RU2300373C2 (https=)
TW (1) TWI312679B (https=)
WO (1) WO2002067925A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142548A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a nerve gas-induced disease comprising the same
US9682059B2 (en) 2013-03-12 2017-06-20 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033093A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
CA2580640A1 (en) * 2004-09-16 2006-03-30 Janssen Pharmaceutica N.V. Methods of treating epileptogensis and epilepsy
MX2007004491A (es) * 2004-10-15 2007-08-08 Johnson & Johnson Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
AU2005335241B9 (en) * 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
CN101657195A (zh) * 2006-10-06 2010-02-24 詹森药业有限公司 氨基甲酸(s)-(+)-2-(2-氯代苯基)-2-羟基乙酯的新型晶体
CA2667949A1 (en) * 2006-10-30 2008-05-08 Janssen Pharmaceutica N.V. Methods for treating depression
MX2009004798A (es) * 2006-10-31 2009-08-12 Janssen Pharmaceutica Nv Tratamiento de los trastornos generalizados del desarrollo.
CA2803825C (en) * 2010-07-02 2015-12-29 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US20130060024A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
EP2797880B1 (en) * 2011-12-27 2017-03-01 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating epilepsy
ES3059582T3 (en) 2016-02-29 2026-03-23 Bio Pharm Solutions Co Ltd Sulfamate derivative compounds, processes for preparing them and their uses
ES3035674T3 (en) 2016-12-14 2025-09-08 Sk Biopharmaceuticals Co Ltd Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease
US20220117941A1 (en) * 2018-09-21 2022-04-21 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
JP2023539291A (ja) * 2020-08-31 2023-09-13 バイオ－ファーム ソリューションズ カンパニー リミテッド 神経変性疾患の予防又は治療用フェニルアルキルカルバメート化合物
KR20230051206A (ko) 2020-09-10 2023-04-17 (주)바이오팜솔루션즈 정신질환 치료 또는 완화용 설파메이트 유도체 화합물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US6403759B2 (en) * 1996-08-02 2002-06-11 Duke University Polymers for delivering nitric oxide in vivo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3278380A (en) * 1962-02-06 1966-10-11 Armour Pharma Methods of calming employing diphenyl hydroxy carbamate compounds
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
CN1109880A (zh) * 1994-02-03 1995-10-11 合成实验室公司 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
MXPA03007717A (es) * 2001-02-27 2005-11-08 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o tratamiento de trastornos bipolares.
CN1262272C (zh) * 2001-02-27 2006-07-05 奥索-麦克尼尔药品公司 用于预防或治疗运动障碍的氨基甲酸酯化合物
US6541513B2 (en) * 2001-02-27 2003-04-01 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating psychotic disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US6403759B2 (en) * 1996-08-02 2002-06-11 Duke University Polymers for delivering nitric oxide in vivo

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014142548A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a nerve gas-induced disease comprising the same
WO2014142549A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same
WO2014142547A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for neuroprotection comprising the same
WO2014142550A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same
US9457003B2 (en) 2013-03-12 2016-10-04 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a nerve gas-induced disease comprising the same
US9566261B2 (en) 2013-03-12 2017-02-14 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a memory loss-related disease comprising the same
KR20170058447A (ko) * 2013-03-12 2017-05-26 (주)바이오팜솔루션즈 페닐카바메이트 화합물 및 이를 포함하는 신경보호용 조성물
US9682059B2 (en) 2013-03-12 2017-06-20 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome
US9872847B2 (en) 2013-03-12 2018-01-23 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating a movement disorder
US9907776B2 (en) 2013-03-12 2018-03-06 Bio-Pharm Solutions, Co., Ltd. Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same
KR102014615B1 (ko) * 2013-03-12 2019-08-27 (주)바이오팜솔루션즈 페닐카바메이트 화합물 및 이를 포함하는 신경보호용 조성물
US10525030B2 (en) 2013-03-12 2020-01-07 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for neuroprotection comprising the same

Also Published As

Publication number Publication date
KR20030076714A (ko) 2003-09-26
DE60220043T2 (de) 2008-01-10
HUP0303264A2 (hu) 2004-01-28
DK1383489T3 (da) 2007-08-06
CY1106753T1 (el) 2012-05-23
CZ20032313A3 (cs) 2004-08-18
RU2300373C2 (ru) 2007-06-10
MXPA03007718A (es) 2004-11-12
IL157591A (en) 2009-12-24
CA2439295C (en) 2010-05-25
CN1235579C (zh) 2006-01-11
HUP0303264A3 (en) 2012-07-30
NZ527990A (en) 2006-01-27
JP4276840B2 (ja) 2009-06-10
EP1383489B1 (en) 2007-05-09
ES2284845T3 (es) 2007-11-16
RU2003128982A (ru) 2005-03-10
EP1383489A1 (en) 2004-01-28
AR035756A1 (es) 2004-07-07
PT1383489E (pt) 2007-06-21
ATE361745T1 (de) 2007-06-15
MY138156A (en) 2009-04-30
US20020165273A1 (en) 2002-11-07
NO20033798D0 (no) 2003-08-26
HK1060516A1 (en) 2004-08-13
RS67403A (sr) 2006-12-15
IL157591A0 (en) 2004-03-28
US20040171679A1 (en) 2004-09-02
BR0207645A (pt) 2004-12-28
US20090005442A1 (en) 2009-01-01
HK1065486A1 (en) 2005-02-25
WO2002067925A1 (en) 2002-09-06
CZ301203B6 (cs) 2009-12-09
JP2004523555A (ja) 2004-08-05
CN1503667A (zh) 2004-06-09
DE60220043D1 (de) 2007-06-21
TWI312679B (en) 2009-08-01
RS51055B (sr) 2010-10-31
NO20033798L (no) 2003-09-26
CA2439295A1 (en) 2002-09-06
PL364680A1 (en) 2004-12-13

Similar Documents

Publication Publication Date Title
KR100910928B1 (ko) 신경퇴행성 질환의 예방 또는 치료용의 카바메이트 화합물 함유 약제학적 조성물
US20090137652A1 (en) Methods for neuroprotection
US20100004244A1 (en) Use of cb2 receptor agonists for promoting neurogenesis
MX2007004491A (es) Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
AU2002247203B2 (en) Carbamate compounds for use in preventing or treating neurodegenerative disordrers
HK1060516B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
AU2002247203A1 (en) Carbamate compounds for use in preventing or treating neurodegenerative disordrers
HK1065486B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120731

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120731

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000